vs
Ardmore Shipping Corp（ASC）与Beam Therapeutics Inc.（BEAM）财务数据对比。点击上方公司名可切换其他公司
Beam Therapeutics Inc.的季度营收约是Ardmore Shipping Corp的1.4倍（$114.1M vs $81.2M），Beam Therapeutics Inc.净利率更高（214.1% vs 15.7%，领先198.4%），Beam Therapeutics Inc.同比增速更快（279.5% vs -15.5%）
阿德莫尔航运是一家全球化海上运输企业，持有并运营中型成品油轮与化学品运输船队，可为全球能源、化工及贸易领域客户提供石油产品、特种化学品及其他散装液态货物的海运服务。
Beam Therapeutics是一家美国生物技术企业，专注于基因治疗与基因组编辑领域的研发，总部位于马萨诸塞州剑桥市。公司依托CRISPR碱基编辑和先导编辑技术，可通过酶促作用修改DNA序列中的单个核苷酸，且不会造成DNA双链断裂，以此开发相关治疗方案。
ASC vs BEAM — 直观对比
营收规模更大
BEAM
是对方的1.4倍
$81.2M
营收增速更快
BEAM
高出295.0%
-15.5%
净利率更高
BEAM
高出198.4%
15.7%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $81.2M | $114.1M |
| 净利润 | $12.8M | $244.3M |
| 毛利率 | — | — |
| 营业利润率 | 16.1% | -15.3% |
| 净利率 | 15.7% | 214.1% |
| 营收同比 | -15.5% | 279.5% |
| 净利润同比 | -47.0% | 370.4% |
| 每股收益（稀释后） | $0.30 | $2.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASCBEAM
| Q4 25 | — | $114.1M | ||
| Q3 25 | $81.2M | — | ||
| Q2 25 | $72.0M | — | ||
| Q1 25 | $74.0M | — | ||
| Q3 24 | $96.1M | — | ||
| Q2 24 | $121.3M | — | ||
| Q1 24 | $106.3M | — | ||
| Q4 23 | — | $316.2M |
净利润ASCBEAM
| Q4 25 | — | $244.3M | ||
| Q3 25 | $12.8M | — | ||
| Q2 25 | $9.6M | — | ||
| Q1 25 | $6.3M | — | ||
| Q3 24 | $24.1M | — | ||
| Q2 24 | $62.7M | — | ||
| Q1 24 | $39.2M | — | ||
| Q4 23 | — | $142.8M |
营业利润率ASCBEAM
| Q4 25 | — | -15.3% | ||
| Q3 25 | 16.1% | — | ||
| Q2 25 | 13.5% | — | ||
| Q1 25 | 8.6% | — | ||
| Q3 24 | 25.4% | — | ||
| Q2 24 | 51.3% | — | ||
| Q1 24 | 37.2% | — | ||
| Q4 23 | — | 42.0% |
净利率ASCBEAM
| Q4 25 | — | 214.1% | ||
| Q3 25 | 15.7% | — | ||
| Q2 25 | 13.3% | — | ||
| Q1 25 | 8.5% | — | ||
| Q3 24 | 25.1% | — | ||
| Q2 24 | 51.7% | — | ||
| Q1 24 | 36.9% | — | ||
| Q4 23 | — | 45.2% |
每股收益（稀释后）ASCBEAM
| Q4 25 | — | $2.53 | ||
| Q3 25 | $0.30 | — | ||
| Q2 25 | $0.22 | — | ||
| Q1 25 | $0.14 | — | ||
| Q3 24 | $0.55 | — | ||
| Q2 24 | $1.47 | — | ||
| Q1 24 | $0.92 | — | ||
| Q4 23 | — | $1.91 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.2B |
| 总债务越低越好 | $116.1M | — |
| 股东权益账面价值 | $628.2M | $1.2B |
| 总资产 | $799.8M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.18× | — |
8季度趋势，按日历期对齐
现金及短期投资ASCBEAM
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | $1.2B |
总债务ASCBEAM
| Q4 25 | — | — | ||
| Q3 25 | $116.1M | — | ||
| Q2 25 | $25.0M | — | ||
| Q1 25 | $20.5M | — | ||
| Q3 24 | $22.5M | — | ||
| Q2 24 | $44.2M | — | ||
| Q1 24 | $23.1M | — | ||
| Q4 23 | — | — |
股东权益ASCBEAM
| Q4 25 | — | $1.2B | ||
| Q3 25 | $628.2M | — | ||
| Q2 25 | $618.3M | — | ||
| Q1 25 | $610.7M | — | ||
| Q3 24 | $627.0M | — | ||
| Q2 24 | $617.7M | — | ||
| Q1 24 | $567.9M | — | ||
| Q4 23 | — | $981.3M |
总资产ASCBEAM
| Q4 25 | — | $1.5B | ||
| Q3 25 | $799.8M | — | ||
| Q2 25 | $703.8M | — | ||
| Q1 25 | $690.4M | — | ||
| Q3 24 | $722.8M | — | ||
| Q2 24 | $742.0M | — | ||
| Q1 24 | $704.1M | — | ||
| Q4 23 | — | $1.5B |
负债/权益比ASCBEAM
| Q4 25 | — | — | ||
| Q3 25 | 0.18× | — | ||
| Q2 25 | 0.04× | — | ||
| Q1 25 | 0.03× | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.07× | — | ||
| Q1 24 | 0.04× | — | ||
| Q4 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.9M | $-83.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-87.0M |
| 自由现金流率自由现金流/营收 | — | -76.3% |
| 资本支出强度资本支出/营收 | — | 3.3% |
| 现金转化率经营现金流/净利润 | 1.40× | -0.34× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASCBEAM
| Q4 25 | — | $-83.3M | ||
| Q3 25 | $17.9M | — | ||
| Q2 25 | $11.2M | — | ||
| Q1 25 | $26.3M | — | ||
| Q3 24 | $39.9M | — | ||
| Q2 24 | $48.4M | — | ||
| Q1 24 | $49.2M | — | ||
| Q4 23 | — | $135.1M |
自由现金流ASCBEAM
| Q4 25 | — | $-87.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | $131.5M |
自由现金流率ASCBEAM
| Q4 25 | — | -76.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | 41.6% |
资本支出强度ASCBEAM
| Q4 25 | — | 3.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | 1.1% |
现金转化率ASCBEAM
| Q4 25 | — | -0.34× | ||
| Q3 25 | 1.40× | — | ||
| Q2 25 | 1.17× | — | ||
| Q1 25 | 4.20× | — | ||
| Q3 24 | 1.65× | — | ||
| Q2 24 | 0.77× | — | ||
| Q1 24 | 1.25× | — | ||
| Q4 23 | — | 0.95× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASC
暂无分部数据
BEAM
| Pfizer | $109.1M | 96% |
| Other | $5.0M | 4% |
